Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Competition from within

    August 25, 2015 | emerging markets 

    Published in eyeforpharma July 29 by Rachel Howard

    To what extent can Big Pharma expect to face an increasing challenge from globalizing pharmaceutical companies based in emerging markets?

    If we take a look at the top 50 pharmaceutical companies of 2013, they are mainly headquartered in North America (18), the EU (18) or Japan (9). Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy – which have since merged – the only representation from the ‘BRIC’ markets (Brazil, Russia, India and China). In ten years’ time, will more ‘home-grown’ emerging market companies feature on this list?

    In this article, I will explore and compare the directions the domestic pharmaceutical industries of South Korea, China and Brazil have taken in recent years, and consider what threat, if any, each poses to established pharmaceutical companies on a global scale.

    Read the full article here http://www.researchpartnership.com/news/2015/07/competition-from-within/

    This content was provided by Inizio

    Company Details

    - PMLiVE

    Inizio

    Email
    Website

     Latest Content from  Inizio 

    Infographic: LATAM

    Latin AmericaThe LATAM regions largest markets of Argentina, Brazil, Chile, Colombia, Mexico and Venezuela, is home to more than 460 million people and is a key global growth region. With...

    Infographic: RA market snapshot

    An overview of the RA biologic patientOur RA market snapshot will provide you with an introduction to the treatment pathways followed by RA patients treated with biologic agents. Our analyses...

    Infographic: CEE

    The Central and Eastern Europe region is home to over 145 million people and is a key global growth region. With pharmaceutical sales set to exceed $27bn in 2014, it...

    Infographic: ASEAN-6

    Home to over half a billion people, the ASEAN region constitutes the eighth largest economy in the world. With pharmaceutical sales projected to exceed $20 billion in 2014, it’s an...

    Infographic: HCV – The Roadblocks to Effective Treatment

    Referencing data from our Living with HCV survey undertaken with patients in the US and China, this infographic explores the roadblocks encountered on the path to effective and compliant treatment.Hepatitis C is...

    Turkey: Identifying the Growth Drivers

    Published in eye for pharma 3 April by Marc Yates

    Article: The Patient Abroad

    Published in Medical Marketing & Media March 2015

    A guide to measuring and tracking brand KPIs

    Dr Allison Fleetwood, Director of Therapy Watch, alongside Associate Director Jennifer Redfearn, recently delivered a workshop on measuring and tracking brand KPIs as part of the BHBIA training programme (www.bhbia.org.uk).

    Electronic medical records and doctor/patient communication

    View from the US: When I talk to family members or friends who are physicians these days, I hear a lot of complaints.

    Statistics and bikinis – 2 men united

    I want to write today about 2 men that between them have reminded me of a fine line that we have to tread every time we analyse a dataset...